Pulse Biosciences Inc. Announces Successful Initial Procedures in PRECISE-BTN Study for Benign Thyroid Nodule Treatment

Reuters

09/02

<a href="https://laohu8.com/S/PLSE">Pulse Biosciences</a> Inc. Announces Successful Initial Procedures in PRECISE-BTN Study for Benign Thyroid Nodule Treatment

Pulse Biosciences Inc. has announced the successful commencement of procedures in the PRECISE Benign Thyroid Nodule (BTN) Study, utilizing its proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology. This multicenter clinical study, approved by the IRB, is designed to treat benign thyroid nodules using the nsPFA™ Percutaneous Electrode System. The study aims to enroll up to 50 patients across four sites, with follow-up evaluations at 1, 3, 6, and 12 months to assess safety, nodule volume reduction, symptom reduction, and quality of life improvements. Initial procedures have been successfully conducted, and early positive results are being observed, with further updates anticipated as patient follow-ups continue.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulse Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250902946787) on September 02, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2564305809"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2564305809\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2564305809?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-02 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564305809","market":"us","top_or_hot":-1,"title":"Pulse Biosciences Inc. Announces Successful Initial Procedures in PRECISE-BTN Study for Benign Thyroid Nodule Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PLSE\">Pulse Biosciences</a> Inc. Announces Successful Initial Procedures in PRECISE-BTN Study for Benign Thyroid Nodule Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Pulse Biosciences Inc. has announced the successful commencement of procedures in the PRECISE Benign Thyroid Nodule (BTN) Study, utilizing its proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology. This multicenter clinical study, approved by the IRB, is designed to treat benign thyroid nodules using the nsPFA™ Percutaneous Electrode System. The study aims to enroll up to 50 patients across four sites, with follow-up evaluations at 1, 3, 6, and 12 months to assess safety, nodule volume reduction, symptom reduction, and quality of life improvements. Initial procedures have been successfully conducted, and early positive results are being observed, with further updates anticipated as patient follow-ups continue.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulse Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250902946787) on September 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pulse Biosciences Inc. Announces Successful Initial Procedures in PRECISE-BTN Study for Benign Thyroid Nodule Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPulse Biosciences Inc. Announces Successful Initial Procedures in PRECISE-BTN Study for Benign Thyroid Nodule Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-02 19:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PLSE\">Pulse Biosciences</a> Inc. Announces Successful Initial Procedures in PRECISE-BTN Study for Benign Thyroid Nodule Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Pulse Biosciences Inc. has announced the successful commencement of procedures in the PRECISE Benign Thyroid Nodule (BTN) Study, utilizing its proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology. This multicenter clinical study, approved by the IRB, is designed to treat benign thyroid nodules using the nsPFA™ Percutaneous Electrode System. The study aims to enroll up to 50 patients across four sites, with follow-up evaluations at 1, 3, 6, and 12 months to assess safety, nodule volume reduction, symptom reduction, and quality of life improvements. Initial procedures have been successfully conducted, and early positive results are being observed, with further updates anticipated as patient follow-ups continue.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulse Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250902946787) on September 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nNDL33WlHs:1","article_id":"2564305809","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564305809","pubTimestamp":1756810886,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Pulse Biosciences Inc. has announced the successful commencement of procedures in the PRECISE Benign Thyroid Nodule  Study, utilizing its proprietary Nanosecond Pulsed Field Ablation  technology. This multicenter clinical study, approved by the IRB, is designed to treat benign thyroid nodules using the nsPFA Percutaneous Electrode System. The study aims to enroll up to 50 patients across four sites, with follow-up evaluations at 1, 3, 6, and 12 months to assess safety, nodule volume reduction, symptom reduction, and quality of life improvements. Initial procedures have been successfully conducted, and early positive results are being observed, with further updates anticipated as patient follow-ups continue.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","PLSE":"Pulse Biosciences, Inc."},"translate_title":"Pulse Biosciences Inc.宣布在PRECISE-BTN良性甲状腺结节治疗研究中成功进行初始手术","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PLSE":0.9},"content_text":"Pulse Biosciences Inc. Announces Successful Initial Procedures in PRECISE-BTN Study for Benign Thyroid Nodule Treatment\n    \n\n        Pulse Biosciences Inc. has announced the successful commencement of procedures in the PRECISE Benign Thyroid Nodule (BTN) Study, utilizing its proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology. This multicenter clinical study, approved by the IRB, is designed to treat benign thyroid nodules using the nsPFA™ Percutaneous Electrode System. The study aims to enroll up to 50 patients across four sites, with follow-up evaluations at 1, 3, 6, and 12 months to assess safety, nodule volume reduction, symptom reduction, and quality of life improvements. Initial procedures have been successfully conducted, and early positive results are being observed, with further updates anticipated as patient follow-ups continue.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulse Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250902946787) on September 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}